



## **Takeda and Lundbeck Launch New Major Depressive Disorder Online Resource for Physicians**

*UnlockingDepression.com is designed to shed light on the many facets of MDD*

**Deerfield, Illinois– November 8, 2012** –Today Takeda Pharmaceuticals U.S.A., Inc, (Takeda) and Lundbeck jointly announced the launch of [UnlockingDepression.com](http://UnlockingDepression.com), a new website for healthcare professionals. The new resource will describe the complex nature of major depressive disorder (MDD), which can impact proper diagnosis and management and is intended to inform and help providers who treat patients with MDD.

Specifically, [UnlockingDepression.com](http://UnlockingDepression.com) offers insight into the broad constellation of MDD symptoms, while addressing many of the often overlooked emotional, cognitive and physical effects of the disease. These symptoms can cause patients distress or impairment in social, occupational, or other important areas of daily functioning, and are a strong predictor of disease relapse. In addition, the new site seeks to reveal some of the intricacies behind the neurobiology of MDD, and discusses the impact of tolerability on patient adherence to treatment.

Brief videoclips titled “Major Depressive Insights,” by three experts in the field provide their perspective on the multifaceted nature of MDD, and visitors can sign up to receive additional information that can help them stay current on the latest disease information. In one of the clips, Stephen Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego School of Medicine, notes that “the symptoms of depression are fairly profound and they change function.” Reflecting on the importance of managing a patient to complete symptom control, Dr. Stahl adds, “There’s the worry that if patients have residual symptoms that they’ll get depressed again because people that don’t get all the way will have a much higher chance of relapsing even if they take their medicine.”

MDD is a very common, debilitating illness that affects around 121 million people worldwide, according to the World Health Organization (WHO). Depression was the third leading contributor to the global burden of disease in 2004, and is projected by WHO to be the leading contributor to the worldwide burden of disease by 2030.

The prevalence and complexity of MDD remain a growing concern for physicians and those living with the condition. Takeda and Lundbeck are committed to supporting educational programs to advance understanding about the complexities of MDD. For more information, please visit [www.UnlockingDepression.com](http://www.UnlockingDepression.com).

### **Takeda and Lundbeck alliance**

In September 2007, Lundbeck and Takeda formed a strategic alliance for the exclusive co-development and commercialization in the United States and Japan of several compounds in the area of central neuroscience disorders.

### **About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases. Lundbeck’s U.S. business is based in Deerfield, Illinois. To learn more about Lundbeck in the U.S., visit [www.lundbeckus.com](http://www.lundbeckus.com).

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, please visit [www.lundbeck.com](http://www.lundbeck.com).

**About Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc.**

Based in Deerfield, Ill., Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology and cardiovascular disease treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit [www.takeda.us](http://www.takeda.us).

**Contacts**

Ashleigh Duchene  
Lundbeck LLC  
847-282-1164

Jessica Tuquero  
Takeda Pharmaceuticals U.S.A., Inc.  
224-554-2021